Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial.

By E. Kuse, P. Chetchotisakd, C. A. da Cunha, M. Ruhnke, C. Barrios, D. Raghunadharao, J. Sekhon, Antonio T. Freire, V. Ramasubramanian, I. Demeyer and 11 more. The Lancet, 2007

647 citations recorded by the source corpus.

Subfields: Infectious Diseases, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/124074d1cfe3046844f7212e38db375cd8b793d0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Infectious Diseases

1. M. Nucci
2. M. Pfaller
3. D. Diekema

Citations in the corpus

• Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. (2012, background): “Kuse et al 2007 [41] (264; 2003–2004) Micafungin 100 mg/d vs liposomal amphotericin B 3 mg/kg/d Randomized, double blinded Candidemia or invasive candidiasis Hepatic dysfunction .”
• ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients (2016, background): “Fifteen reported primary results from clinical trials.(5-11,13-17,19,20) One publication analyzed results of a subgroup of cancer patients from a previously published trial.”
• Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of America (2009, background): “For empirical treatment of suspected catheter-related candidemia, use an echinocandin or, in selected patients, fluconazole A-II [186, 187, 194, 260] D ow naded rom http/academ ic.”
• Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. (2007, background): “Two recently completed clinical trials further suggest that micafungin is effective for the treatment of invasive candidiasis [24, 25].”
• Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. (2016, background): “Liposomal AmB, 3 mg/kg daily, has been shown to be as effective as micafungin for treatment of candidemia [26].”
• Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America (2009, methodology): “On the basis of data from recent clinical trials [28, 51, 52, 54, 79], step-down therapy to fluconazole is reasonable for patients who have improved clinically after initial therapy with an echinocandin or AmB and who are infected with an organism that is likely to be susceptible to fluconazole (e.”